Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Equity Bottom-Up

Pharmala Biotech Holdings  / Equity Bottom-Up

<div><ul><li>Global MDMA supply leadership. PharmAla has established itself as a leading global supplier of clinical-grade MDMA, supporting ~35 clinical trials, including research at Harvard, Yale, Johns Hopkins, and the US Department of Veterans Affairs.</li><li>Kadysh highlighted manufacturing reliability, regulatory compliance, and repeat orders as key differentiators.</li><li>Drugs-for-data strategy for long-term IP value. PharmAla selectively provides discounted or free drug product in exchange for perpetual licenses that need not be exclusive to granular safety and efficacy outcomes from novel clinical trials. </li></ul></div>

Global MDMA supply leadership. PharmAla has established itself as a leading global supplier of clinical-grade MDMA, supporting ~35 clinical trials, including research at Harvard, Yale, Johns Hopkins, and the US Department of Veterans Affairs.Kadysh highlighted manufacturing reliability, regulatory compliance, and repeat orders as key differentiators.Drugs-for-data strategy for long-term IP value. PharmAla selectively provides discounted or free drug product in exchange for perpetual licenses that need not be exclusive to granular safety and efficacy outcomes from novel clinical trials. 

MDMA: Leveraging MDMA Supply Leadership for Development Optionality and Asset Monetization

<div><ul><li>Supply leadership moat is quality and data, not licensing head start. PharmAla supplies ~35 clinical trials globally, including Johns Hopkins, Harvard, Yale, the VA, and now the US military, with ~30% repeat customers.</li><li>Kadysh argued that the durable advantage is a regulator-accepted dossier (stability, manufacturing quality) and finished drug product rather than bare API, which raises the switching burden mid-program.</li><li>The drugs-for-data arrangements are screened and contractually specific. Kadysh explained that PharmAla secures non-exclusive, perpetual licenses to granular safety and efficacy outcomes, prioritizing novel indications that add to the scientific literature while leaving publication rights with investigators.</li></ul></div>

Supply leadership moat is quality and data, not licensing head start. PharmAla supplies ~35 clinical trials globally, including Johns Hopkins, Harvard, Yale, the VA, and now the US military, with ~30% repeat customers.Kadysh argued that the durable advantage is a regulator-accepted dossier (stability, manufacturing quality) and finished drug product rather than bare API, which raises the switching burden mid-program.The drugs-for-data arrangements are screened and contractually specific. Kadysh explained that PharmAla secures non-exclusive, perpetual licenses to granular safety and efficacy outcomes, prioritizing novel indications that add to the scientific literature while leaving publication rights with investigators.

MDMA: Key Takeaways from WTR Insights Conference

<div><ul><li>Commercial today in a sector that mostly is not. PharmAla Biotech Holdings, Inc. (CSE: MDMA/OTC: MDXXF) sells Current Good Manufacturing Practice (cGMP) MDMA under the LaNeo™ brand into more than 30 clinical trials worldwide and, via the Cortexa JV, into Australia’s regulated prescribing market.</li><li>Product sales of C$2.4M plus C$0.7M of Cortexa license income since FY23 separate it from pre-revenue psychedelic peers.</li><li>Competitive advantage lies in regulatory infrastructure, not manufacturing.</li></ul></div>

Commercial today in a sector that mostly is not. PharmAla Biotech Holdings, Inc. (CSE: MDMA/OTC: MDXXF) sells Current Good Manufacturing Practice (cGMP) MDMA under the LaNeo™ brand into more than 30 clinical trials worldwide and, via the Cortexa JV, into Australia’s regulated prescribing market.Product sales of C$2.4M plus C$0.7M of Cortexa license income since FY23 separate it from pre-revenue psychedelic peers.Competitive advantage lies in regulatory infrastructure, not manufacturing.

MDMA: Monetizing Regulatory Advantage Through IP and Data

<ul><li>PharmAla hit a commercial inflection in 3QFY26. </li><li>Revenue of C$513,232 was up 3.8x Y/Y and nine-month revenue roughly tripled to C$1,000,256.</li><li>Gross profit rose ~170% in the quarter to C$338,545 from C$125,549. </li></ul>

PharmAla hit a commercial inflection in 3QFY26. Revenue of C$513,232 was up 3.8x Y/Y and nine-month revenue roughly tripled to C$1,000,256.Gross profit rose ~170% in the quarter to C$338,545 from C$125,549. 

<ul><li>Strategic pivot to a capital-light, IP-licensing model. PharmAla is deliberately shifting toward a capital-light model in which partners fund development while the company contributes its IP.</li><li>Management cites the Restora SPV spin-out of APA-01, repositioned as a neurology, non-controlled-substance asset, and the proposed US licensing transaction for ALA-002 with Jupiter Neurosciences as transformational.</li><li>If completed, the combined licensing transactions could generate ~US$4 million in value, substantially exceeding management’s current expectation of ~$2 million in annual product sales across Australia and international markets on a go-forward basis.</li></ul>

Strategic pivot to a capital-light, IP-licensing model. PharmAla is deliberately shifting toward a capital-light model in which partners fund development while the company contributes its IP.Management cites the Restora SPV spin-out of APA-01, repositioned as a neurology, non-controlled-substance asset, and the proposed US licensing transaction for ALA-002 with Jupiter Neurosciences as transformational.If completed, the combined licensing transactions could generate ~US$4 million in value, substantially exceeding management’s current expectation of ~$2 million in annual product sales across Australia and international markets on a go-forward basis.

MDMA: From MDMA Supply Chain to Data Advantage

Canada

Pharmala Biotech Holdings Inc. operates as a biotech company. The Company focuses on domestic research, development, and manufacturing of clinical-grade MDMA and novel MDXX compounds in service to the scientific research community. Pharmala Biotech Holdings serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Pharmala Biotech Holdings (MDMA CN)

MDMA: Leveraging MDMA Supply Leadership for Development Optionality and Asset Monetization

Global MDMA supply leadership. PharmAla has established itself as a leading global supplier of clinical-grade MDMA, supporting ~35 clinical trials,...

Water Tower Research

MDMA: Key Takeaways from WTR Insights Conference

Supply leadership moat is quality and data, not licensing head start. PharmAla supplies ~35 clinical trials globally, including Johns Hopkins,...

Water Tower Research

MDMA: Monetizing Regulatory Advantage Through IP and Data

Product sales of C$2.4M plus C$0.7M of Cortexa license income since FY23 separate it from pre-revenue psychedelic peers.Competitive advantage lies...

Water Tower Research

MDMA: Revenue from Supply, Value from IP

PharmAla hit a commercial inflection in 3QFY26. Revenue of C$513,232 was up 3.8x Y/Y and nine-month revenue roughly tripled to C$1,000,256.

Water Tower Research

MDMA: From MDMA Supply Chain to Data Advantage

PharmAla is deliberately shifting toward a capital-light model in which partners fund development while the company contributes its IP.

Water Tower Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)